Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Pfizenmaier

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Cytokine & Growth Factor Reviews|March 1, 2005
Tumor therapeutics by design: targeting and activation of death receptorsHarald Wajant, Jeannette Gerspach, Klaus Pfizenmaier
Results and Problems in Cell Differentiation|January 15, 2009
Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligandsJeannette Gerspach, Harald Wajant, Klaus Pfizenmaier
Cytokine & Growth Factor Reviews|December 18, 2002
Non-apoptotic Fas signalingHarald Wajant, Klaus Pfizenmaier, Peter Scheurich
Recent Patents on Anti-Cancer Drug Discovery|July 19, 2011
Therapeutic targeting of CD95 and the TRAIL death receptorsJeannette Gerspach, Klaus Pfizenmaier, Harald Wajant
Cancer Letters|January 18, 2011
Engineering death receptor ligands for cancer therapyHarald Wajant, Jeannette Gerspach, Klaus Pfizenmaier
Biofactors (Oxford, England)|June 2, 2009
Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effectsJeannette Gerspach, Klaus Pfizenmaier, Harald Wajant
Expert Opinion on Drug Discovery|March 16, 2013
Antagonists of TNF action: clinical experience and new developmentsRoland E Kontermann, Peter Scheurich, Klaus Pfizenmaier
Frontiers in Cell and Developmental Biology|June 13, 2020
Selective Targeting of TNF Receptors as a Novel Therapeutic ApproachRoman Fischer, Roland E Kontermann, Klaus Pfizenmaier
Molecular Endocrinology (Baltimore, Md.)|April 2, 2004
Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cellsMiriam B Buck, Klaus Pfizenmaier, Cornelius Knabbe
Biochemical and Biophysical Research Communications|May 8, 2010
Superior serum half life of albumin tagged TNF ligandsNicole Müller, Britta Schneider, Klaus Pfizenmaier, et al.
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Cytokine & Growth Factor Reviews|March 1, 2005
Tumor therapeutics by design: targeting and activation of death receptorsHarald Wajant, Jeannette Gerspach, Klaus Pfizenmaier
Results and Problems in Cell Differentiation|January 15, 2009
Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligandsJeannette Gerspach, Harald Wajant, Klaus Pfizenmaier
Cytokine & Growth Factor Reviews|December 18, 2002
Non-apoptotic Fas signalingHarald Wajant, Klaus Pfizenmaier, Peter Scheurich
Recent Patents on Anti-Cancer Drug Discovery|July 19, 2011
Therapeutic targeting of CD95 and the TRAIL death receptorsJeannette Gerspach, Klaus Pfizenmaier, Harald Wajant
Cancer Letters|January 18, 2011
Engineering death receptor ligands for cancer therapyHarald Wajant, Jeannette Gerspach, Klaus Pfizenmaier
Biofactors (Oxford, England)|June 2, 2009
Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effectsJeannette Gerspach, Klaus Pfizenmaier, Harald Wajant
Expert Opinion on Drug Discovery|March 16, 2013
Antagonists of TNF action: clinical experience and new developmentsRoland E Kontermann, Peter Scheurich, Klaus Pfizenmaier
Frontiers in Cell and Developmental Biology|June 13, 2020
Selective Targeting of TNF Receptors as a Novel Therapeutic ApproachRoman Fischer, Roland E Kontermann, Klaus Pfizenmaier
Molecular Endocrinology (Baltimore, Md.)|April 2, 2004
Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cellsMiriam B Buck, Klaus Pfizenmaier, Cornelius Knabbe
Biochemical and Biophysical Research Communications|May 8, 2010
Superior serum half life of albumin tagged TNF ligandsNicole Müller, Britta Schneider, Klaus Pfizenmaier, et al.
Pageof 10